News - Astellas Pharma, Vibativ

Filter

Current filters:

Astellas PharmaVibativ

Popular Filters

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane

12-03-2013

UK-based Clinigen Group (LSE: CLIN ) and Theravance (Nasdaq: THRX) of the USA have entered into an exclusive…

Antibiotics and Infectious diseasesAstellas PharmaceftolozaneClinigen GroupCubist PharmaceuticalsEuropeGlobalLicensingPharmaceuticalTheravanceVibativ

Astellas pulls out of deal with Theravance

09-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

Astellas get EU approval for Vibativ for nosocomial pneumonia caused by MRSA

15-09-2011

The European Commission has granted marketing authorization for Japanese drug major Astellas’ (TYO:…

Antibiotics and Infectious diseasesAstellas PharmaEuropePharmaceuticalRegulationTheravanceVibativ

Back to top